Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...
A recent review and meta-analysis of semaglutide studies found that this drug can significantly reduce the risk of ...
8h
ThePrint on MSNIn Brazil’s São Paulo, armed gangs on the hunt for something more sought-after than gold—OzempicDesperation for ‘weight-loss’ drug that’s used to treat type-2 diabetes is real. Break-ins at pharmacies have also been ...
Researchers said the study backs up anecdotal evidence from patients and doctors that semaglutide can lead to a sudden loss ...
American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic anterior optic neuropathy (NAION).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results